SAN DIEGO—(BUSINESS WIRE)—
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceuticalcompany utilizing innovative technology to fuel drug discovery andclinical development of novel treatments for central nervous systemdisorders, today announced that it will present at the followinginvestor conferences:
—The BIOCOM Investor Conference 2008 on Tuesday, October 28,2008, at 3:30 p.m. Pacific Time at the Hyatt Regency in SanDiego.—BIO InvestorForum 2008 on Thursday, October 30, 2008, at 12:00p.m. Pacific Time at The Palace Hotel in San Francisco.
Live webcasts of these presentations will be accessible on thecompany's website, www.acadia-pharm.com, under the investors sectionand an archived recording will be available on the website for twoweeks following the presentation.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA is focused ondeveloping a portfolio of its four most advanced product candidates,including pimavanserin in Phase III for Parkinson's disease psychosis,a compound in Phase II for chronic pain and a compound in Phase I forglaucoma, both in collaboration with Allergan, and ACP-106 inIND-track development. All of the product candidates in ACADIA'spipeline emanate from discoveries made using its proprietary drugdiscovery platform and are directed at indications with large unmetmedical needs. ACADIA's corporate headquarters is located in SanDiego, California and it maintains research and development operationsin both San Diego and Malmo, Sweden.
Source: ACADIA Pharmaceuticals Inc.